|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: E2F5 |
Gene summary for E2F5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | E2F5 | Gene ID | 1875 |
| Gene name | E2F transcription factor 5 | |
| Gene Alias | E2F-5 | |
| Cytomap | 8q21.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q15329 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1875 | E2F5 | HCC1_Meng | Human | Liver | HCC | 1.37e-77 | 3.53e-01 | 0.0246 |
| 1875 | E2F5 | HCC2_Meng | Human | Liver | HCC | 3.12e-13 | 4.03e-02 | 0.0107 |
| 1875 | E2F5 | S014 | Human | Liver | HCC | 5.78e-04 | 1.86e-01 | 0.2254 |
| 1875 | E2F5 | S015 | Human | Liver | HCC | 4.32e-03 | 2.34e-01 | 0.2375 |
| 1875 | E2F5 | S016 | Human | Liver | HCC | 2.44e-02 | 1.60e-01 | 0.2243 |
| 1875 | E2F5 | S027 | Human | Liver | HCC | 3.04e-07 | 5.03e-01 | 0.2446 |
| 1875 | E2F5 | S028 | Human | Liver | HCC | 6.91e-26 | 7.44e-01 | 0.2503 |
| 1875 | E2F5 | S029 | Human | Liver | HCC | 2.21e-13 | 5.74e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa0421822 | Liver | HCC | Cellular senescence | 102/4020 | 156/8465 | 4.18e-06 | 3.59e-05 | 2.00e-05 | 102 |
| hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa0421832 | Liver | HCC | Cellular senescence | 102/4020 | 156/8465 | 4.18e-06 | 3.59e-05 | 2.00e-05 | 102 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| E2F5 | TAC | Colorectum | CRC | LEFTY1,IGKC,PSMA7, etc. | 3.70e-01 |  |
| E2F5 | CILIA | Endometrium | ADJ | LINC01128,AC009404.1,MEF2B, etc. | 1.67e-01 |  |
| E2F5 | CILIA | Endometrium | EEC | LINC01128,AC009404.1,MEF2B, etc. | 1.62e-01 |  |
| E2F5 | MDSCs | Esophagus | ESCC | ITGB5,SHOX2,MBD2, etc. | 9.16e-02 |  |
| E2F5 | PLA | Lung | AIS | TRIM5,RAB30,SP140, etc. | 7.54e-02 |  |
| E2F5 | BN | Lung | AIS | TRIM5,RAB30,SP140, etc. | 1.21e-01 | |
| E2F5 | MALTB | Lung | AIS | TRIM5,RAB30,SP140, etc. | 1.10e-01 | |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| E2F5 | SNV | Missense_Mutation | novel | c.910G>A | p.Asp304Asn | p.D304N | Q15329 | protein_coding | deleterious(0.02) | possibly_damaging(0.527) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| E2F5 | SNV | Missense_Mutation | novel | c.146N>A | p.Ser49Asn | p.S49N | Q15329 | protein_coding | tolerated(0.06) | benign(0.398) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| E2F5 | SNV | Missense_Mutation | novel | c.231A>T | p.Lys77Asn | p.K77N | Q15329 | protein_coding | deleterious(0) | benign(0.393) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| E2F5 | SNV | Missense_Mutation | c.633N>T | p.Lys211Asn | p.K211N | Q15329 | protein_coding | deleterious(0.03) | benign(0.168) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| E2F5 | SNV | Missense_Mutation | novel | c.635N>C | p.Lys212Thr | p.K212T | Q15329 | protein_coding | deleterious(0) | possibly_damaging(0.627) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| E2F5 | SNV | Missense_Mutation | c.500A>T | p.Asn167Ile | p.N167I | Q15329 | protein_coding | deleterious(0.02) | possibly_damaging(0.781) | TCGA-AH-6544-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
| E2F5 | deletion | Frame_Shift_Del | rs761281897 | c.320delA | p.Lys107SerfsTer11 | p.K107Sfs*11 | Q15329 | protein_coding | TCGA-AZ-4615-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | xeloda | PD | ||
| E2F5 | deletion | Frame_Shift_Del | rs761281897 | c.320delA | p.Lys107SerfsTer11 | p.K107Sfs*11 | Q15329 | protein_coding | TCGA-F4-6856-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR | ||
| E2F5 | deletion | Frame_Shift_Del | rs761281897 | c.320delA | p.Lys107SerfsTer11 | p.K107Sfs*11 | Q15329 | protein_coding | TCGA-G4-6304-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | PD | ||
| E2F5 | SNV | Missense_Mutation | c.506G>T | p.Arg169Ile | p.R169I | Q15329 | protein_coding | tolerated(0.1) | benign(0.096) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |